More drug companies are racing to join what’s been a two-horse race to make blockbuster obesity drugs, snapping up smaller biotechs and vying for a market that could be worth tens of billions in less than a decade. GLP-1 agonists like Novo Nordisk’s Wegovy and Ozempic have soared in popularity despite high price tags, mixed insurance coverage and a number of unpleasant side effects. The market is expected to top $100 billion by 2030 and is ripe for new entrants, as drugmakers struggle to keep up with demand. And should Medicare ultimately cover weight-loss drugs, that would take things to another order of magnitude.
Read the full article: The Weight-Loss Drug Gold Rush Is Getting Larger //
Source: https://www.axios.com/2023/12/05/weight-loss-drugs-develop-roche